Wall Street looks bullish on Biogen’s (BIIB) prospects after the company’s success during the Phase 3 clinical trial of lecanemab. The drug could boost the company’s financials significantly as it…
© 2023 The Abundance Pub. All rights reserved.
All trademarks and service marks are the property of their respective owners. This site is not intended to provide, and does not constitute, medical, health, legal, investment, financial or other professional advice.